Zhejiang East-Asia Pharmaceutical Co Ltd Class A 605177
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 25.09
- Day Range
- CNY 24.50–25.44
- 52-Week Range
- CNY 14.96–34.89
- Bid/Ask
- CNY 24.57 / CNY 24.59
- Market Cap
- CNY 2.79 Bil
- Volume/Avg
- 873,500 / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 30.20
- Price/Sales
- 2.39
- Dividend Yield (Trailing)
- 1.16%
- Dividend Yield (Forward)
- 1.16%
- Total Yield
- 1.13%
Company Profile
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,435
- Website
- http://www.eapharm.cn
Comparables
Valuation
|
Metric
|
605177
|
688506
|
600285
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.20 | 16.75 | 23.69 |
Price/Book Value | 1.45 | 14.16 | 4.76 |
Price/Sales | 2.39 | 12.38 | 4.06 |
Price/Cash Flow | — | 14.75 | 17.93 |
Price/Earnings
605177
688506
600285
Financial Strength
|
Metric
|
605177
|
688506
|
600285
|
|---|---|---|---|
Quick Ratio | 1.49 | 0.69 | 1.02 |
Current Ratio | 2.49 | 0.94 | 1.33 |
Interest Coverage | 34.61 | −21.76 | — |
Quick Ratio
605177
688506
600285
Profitability
|
Metric
|
605177
|
688506
|
600285
|
|---|---|---|---|
Return on Assets (Normalized) | 3.47% | 166.42% | 12.44% |
Return on Equity (Normalized) | 5.40% | 307.42% | 21.12% |
Return on Invested Capital (Normalized) | 3.92% | 219.82% | 19.26% |
Return on Assets
605177
688506
600285
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tfyldhmjsw | Bqdct | $605.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Stwhgnjdd | Znjvdb | $116.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jxkxghtv | Btxmrb | $108.0 Bil | |
MRNA
| Moderna Inc | Wqvrdbxv | Yyk | $62.9 Bil | |
BNTX
| BioNTech SE ADR | Njkgcypz | Yjxx | $23.9 Bil | |
ARGX
| argenx SE ADR | Clcrzwm | Csknl | $22.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ncgrhsdw | Pxcxbr | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tbyvfxl | Vbwdclq | $14.5 Bil | |
INCY
| Incyte Corp | Bwbtvmhg | Fnwgdmh | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jyssslqcm | Rpbywr | $12.3 Bil |